UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Tumor Heterogeneity Confounds and Illuminates: Assessing the implications

Nature medicine, 2014-04, Vol.20 (4), p.342-344

2014

Volltextzugriff (PDF)

Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms

Cancer cell, 2018-01, Vol.33 (1), p.29-43.e7

2018

Volltextzugriff (PDF)

JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response

Cancer discovery, 2015-03, Vol.5 (3), p.316-331

2015

Volltextzugriff (PDF)

Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms

Blood, 2014-03, Vol.123 (13), p.2075-2083

2014

Volltextzugriff (PDF)

Underlying Causes and Therapeutic Targeting of the Inflammatory Tumor Microenvironment

Frontiers in cell and developmental biology, 2018-06, Vol.6, p.56

2018

Volltextzugriff (PDF)

TRAF6 Mediates Basal Activation of NF-κB Necessary for Hematopoietic Stem Cell Homeostasis

Cell reports (Cambridge), 2018-01, Vol.22 (5), p.1250-1262

2018

Volltextzugriff (PDF)

Endothelial-specific inhibition of NF-κB enhances functional haematopoiesis

Nature communications, 2016-12, Vol.7 (1), p.13829-13829, Article 13829

2016

Volltextzugriff (PDF)

LSD1 Inhibition Prolongs Survival in Mouse Models of MPN by Selectively Targeting the Disease Clone

HemaSphere, 2018-06, Vol.2 (3), p.e54-n/a

2018

Volltextzugriff (PDF)

Mathematical modeling reveals alternative JAK inhibitor treatment in myeloproliferative neoplasms

Haematologica (Roma), 2020-03, Vol.105 (3), p.e91-e94

2020

Volltextzugriff (PDF)

Tumor heterogeneity confounds and illuminates

Nature medicine, 2014-04, p.342

2014

Volltextzugriff (PDF)

Mutation analysis of the tyrosine phosphatase PTPN2 in Hodgkin’s lymphoma and T-cell non-Hodgkin’s lymphoma

Haematologica (Roma), 2011-11, Vol.96 (11), p.1723-1727

2011

Volltextzugriff (PDF)

Hsp90 inhibition disrupts JAK-STAT signaling and leads to reductions in splenomegaly in patients with myeloproliferative neoplasms

Haematologica (Roma), 2018-01, Vol.103 (1), p.e5-e9

2018

Volltextzugriff (PDF)

Correction: Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group's clinical trial E3999

Blood cancer journal (New York), 2023-07, Vol.13 (1), p.103-103, Article 103

2023

Volltextzugriff (PDF)

Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group's clinical trial E3999

Blood cancer journal (New York), 2022-09, Vol.12 (9), p.137-137, Article 137

2022

Volltextzugriff (PDF)

MOHITO, a novel mouse cytokine-dependent T-cell line, enables studies of oncogenic signaling in the T-cell context

Haematologica (Roma), 2011-05, Vol.96 (5), p.779-783

2011

Volltextzugriff (PDF)

Somatic mutations in leukocytes infiltrating primary breast cancers

NPJ breast cancer, 2015-01, Vol.1 (1), p.15005-15005, Article 15005

2015

Volltextzugriff (PDF)

MSC Reprogramming and Aberrant Inflammatory Signaling in Myelofibrosis: Insights from Single-Cell RNA-Sequencing of Trephine Bone Marrow Cells

Blood, 2023-11, Vol.142 (Supplement 1), p.743-743

2023

Volltextzugriff (PDF)

Mutational Analysis of the Genome Stability Factor BOD1L1 in Myeloproliferative Neoplasm

Blood, 2023-11, Vol.142 (Supplement 1), p.5677-5677

2023

Volltextzugriff (PDF)

Abstract P073: Targeting JAK1 signaling for molecular prevention in clonal hematopoiesis

Cancer prevention research (Philadelphia, Pa.), 2023-01, Vol.16 (1_Supplement), p.P073-P073

2023

Volltextzugriff (PDF)

Toll-like receptor alterations in myelodysplastic syndrome

Leukemia, 2013-09, Vol.27 (9), p.1832-1840

2013

Volltextzugriff (PDF)

Tumor heterogeneity confounds and illuminates: assessing the implications

Nature medicine, 2014-04, Vol.20 (4), p.342

2014

Volltextzugriff (PDF)

Assessing the implications

Nature medicine, 2014-04, p.342

2014

Volltextzugriff (PDF)

Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms

The Journal of clinical investigation, 2019-04, Vol.130 (4), p.1596-1611

2019

Volltextzugriff (PDF)

LSD1 Inhibition Enhances Antigen Presentation and Co-Stimulation in AML to Promote T Cell-Mediated Anti-Leukemia Immune Responses

Blood, 2023-11, Vol.142 (Supplement 1), p.6793-6793

2023

Volltextzugriff (PDF)

1 – 25 von 89

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(82)
Mit Volltextzugriff
(72)

Publikationsform

Sprache

Englisch
(88)
Spanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(46)
Life Sciences & Biomedicine
(40)
Humans
(28)
Animals
(20)
Hematology
(17)
Mice
(15)
Oncology
(14)
Mutation
(12)
Cell Biology
(11)
Biological And Medical Sciences
(8)
Female
(8)
Signal Transduction
(8)
Cell Line, Tumor
(7)
Janus Kinase 2 - Genetics
(7)
Myeloproliferative Disorders - Drug Therapy
(7)
Tumors
(7)
Cancer
(6)
Hematologic And Hematopoietic Diseases
(6)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(6)
Medical Sciences
(6)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Tumor Heterogeneity Confounds and Illuminates: Assessing the implications

Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms

JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response

Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms

Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms

Underlying Causes and Therapeutic Targeting of the Inflammatory Tumor Microenvironment

TRAF6 Mediates Basal Activation of NF-κB Necessary for Hematopoietic Stem Cell Homeostasis

Endothelial-specific inhibition of NF-κB enhances functional haematopoiesis

LSD1 Inhibition Prolongs Survival in Mouse Models of MPN by Selectively Targeting the Disease Clone

Mathematical modeling reveals alternative JAK inhibitor treatment in myeloproliferative neoplasms

Tumor heterogeneity confounds and illuminates

Mutation analysis of the tyrosine phosphatase PTPN2 in Hodgkin’s lymphoma and T-cell non-Hodgkin’s lymphoma

Hsp90 inhibition disrupts JAK-STAT signaling and leads to reductions in splenomegaly in patients with myeloproliferative neoplasms

Correction: Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group's clinical trial E3999

Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group's clinical trial E3999

MOHITO, a novel mouse cytokine-dependent T-cell line, enables studies of oncogenic signaling in the T-cell context

Somatic mutations in leukocytes infiltrating primary breast cancers

MSC Reprogramming and Aberrant Inflammatory Signaling in Myelofibrosis: Insights from Single-Cell RNA-Sequencing of Trephine Bone Marrow Cells

Mutational Analysis of the Genome Stability Factor BOD1L1 in Myeloproliferative Neoplasm

Abstract P073: Targeting JAK1 signaling for molecular prevention in clonal hematopoiesis

Toll-like receptor alterations in myelodysplastic syndrome

Tumor heterogeneity confounds and illuminates: assessing the implications

Assessing the implications

Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms

LSD1 Inhibition Enhances Antigen Presentation and Co-Stimulation in AML to Promote T Cell-Mediated Anti-Leukemia Immune Responses

Suchergebnisse filtern